Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort

European Respiratory Journal

Volumn 49, Issue 5, 2017, Pages

  Vandecasteele, Els ^a   Drieghe, Benny ^a   Melsens, Karin ^b   Thevissen, Kristof ^a   De Pauw, Michel ^a   Deschepper, Ellen ^b   Decuman, Saskia ^b   Bonroy, Carolien ^a   Piette, Yves ^a   De Keyser, Filip ^a,b   Brusselle, Guy ^a   Smith, Vanessa ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALGORITHM; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART DISEASE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCREENING; SYSTEMIC SCLEROSIS; UNIVERSITY HOSPITAL; COMPLICATION; COST BENEFIT ANALYSIS; EUROPE; INCIDENCE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROCEDURES; PROSPECTIVE STUDY;

ADULT; ALGORITHMS; CARDIAC CATHETERIZATION; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; EUROPE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 85019130999     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02275-2016     Document Type: Review

References (28)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
2. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
3. Decuman S, Smith V, Verhaeghe S, et al. Work participation and work transition in patients with systemic sclerosis: a cross-sectional study. Rheumatology 2012; 51: 297-304.
4. Hachulla E, Clerson P, Airo P, et al. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology 2015; 54: 1262-1269.
5. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975.
6. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625-1635.
7. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
8. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-1219.
9. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
10. Hachulla E, Launay D, Yaici A, et al. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010; 49: 940-944.
11. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682-691.
12. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576.
13. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-3912.
14. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
15. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
16. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349.
17. Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013; 65: 3194-3201.
18. Hao Y, Thakkar V, Stevens W, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015; 17: 7.
19. Nagaraja V, Visovatti S, Gladue H, et al. Screening algorithm for pulmonary hypertension in systemic sclerosis - comparison of predictive accuracy in three algorithms. Arthritis Rheum 2015; 67: Suppl. 10, 3139.
20. Soukup T, Pudil R, Kubinova K, et al. Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre. Rheumatology 2016; 55: 109-114.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
22. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-1755.
23. Alere. Triage® NT-proBNP Test. Product Insert. http://www.alere.com/en/home/product-details/triage-nt-probnp. html Date last accessed: October 17, 2016.
24. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
25. Bonroy C, Smith V, Van Steendam K, et al. The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies. Clin Chem Lab Med 2013; 51: 2151-2160.
26. Altman DG, Machin D, Bryant T, et al. Statistics with Confidence. 2nd edn. London, BMC Books, 2000.
27. Vandecasteele EH, De Pauw M, Brusselle G, et al. The heart and pulmonary arterial hypertension in systemic sclerosis. Acta Clin Belg 2016; 71: 1-18.
28. Visovatti SH, Distler O, Coghlan JG, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther 2014; 16: 493.